Clinical Review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 9, 2002, Pages 4033-4041

  Rubin, Mishaela R ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GLUCOCORTICOID; PARATHYROID HORMONE;

BONE DENSITY; BONE METABOLISM; BONE REMODELING; CALCANEUS; CALCIUM METABOLISM; COHORT ANALYSIS; DENSITOMETRY; HUMAN; MORPHOMETRICS; OSSIFICATION; OSTEOPOROSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW;

ANIMALS; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 0036736811     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-012101     Document Type: Review

References (103)

1. Cushing H 1932 The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50:137-195
2. Lukert B 1996 Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press; 801-820
3. Adinoff AD, Hollister JR 1983 Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268
4. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000
5. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP 1993 Osteoporosis after cardiac transplantation. Am J Med 94:257-264
6. Rodino MA, Shane E 1998 Osteoporosis after organ transplantation. Am J Med 104:459-469
7. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
8. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH 1996 Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23:995-1000
9. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318
10. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS 2001 Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
11. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR 1991 Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 338:60-61
12. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHivie K, LeBoff MS 2001 Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345:941-947
13. Chavassieux P, Pastoureau P, Chapuy MC, Delmas PD, Meunier PJ 1993 Glucocorricoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int 3:97-102
14. Dempster DW 1989 Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137-141
15. Dempster DW, Arlot MA, Meunier PJ 1983 Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410-417
16. Lane NE, Sanchez S, Modin GW, Genant HK, Ini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633
17. Lukert BP, Raisz LG 1990 Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364
18. Canalis E 1996 Clinical review 83. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:3441-3447
19. Lane NE, Lukert B 1998 The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27:465-483
20. Lukert BP, Raisz LG 1994 Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 20:629-650
21. Reid IR, Evans MC, Wattie DJ, Ames R, Cundy TF 1992 Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int 2:103-105
22. Sambrook P, Birmingham J, Kempler S, Kelly P, Eberl S, Pocock N, Yeates M, Eisman J 1990 Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211-1216
23. Reid IR 1989 Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 30:83-103
24. Canalis E, Giustina A 2001 Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86:5681-5685
25. Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H 1977 Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab 45:488-495
26. Sakakura M, Takebe K, Nakagawa S 1975 Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 40:774-779
27. Hsueh AJ, Erickson GF 1978 Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 32:639-648
28. MacAdams MR, White RH, Chipps BE 1986 Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 104:648-651
29. Reid IR, Ibbertson HK, France JT, Pybus J 1985 Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. Br Med J (Clin Res Ed) 291:574
30. Goulding A, Gold E 1988 Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving β-estradiol. Endocrinology 122:482-487
31. Crilly R, Cawood M, Marshall DH, Nordin BE 1978 Hormonal status tn normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 71:733-736
32. Mateo L, Nolla JM, Bonnin MR, Navarro MA, Roig-Escofet D 1995 Sex hormone status and bone mineral density in men with rheumatoid arthritis. J Rheumatol 22:1455-1460
33. Praet JP, Peretz A, Rozenberg S, Famaey JP, Bourdoux P 1992 Risk of osteoporosis in men with chronic bronchitis. Osteoporos Int 2:257-261
34. Pereira RC, Blanquaert F, Canalis E 1999 Cortisol enhances the expression of mac25/insulin-like growth factor-binding protein-related protein-1 in cultured osteoblasts. Endocrinology 140:228-232
35. Pereira RC, Durant D, Canalis E 2000 Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts. Am J Physiol Endocrinol Metab 279:E570-E576
36. Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM 1996 Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 93:7644-7648
37. Blanquaert F, Delany AM, Canalis E 1999 Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Endocrinology 140:1069-1074
38. Skrtic S, Ohlsson C 2000 Cortisol decreases hepatocyte growth factor levels in human osteoblast-like cells. Calcif Tissue Int 66:108-112
39. Blanquaert F, Pereira RC, Canalis E 2000 Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol Metab 278:E509-E515
40. Danneskiold-Samsoe B, Grimby G 1986 The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis. Clin Sci (Colch) 71:693-701
41. Feldman D, Krishnan AV 1987 Glucocorticoid effects on calcium metabolism and bone in the development of osteopenia. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis. Copenhagen: Osteopress; 1106
42. Rickers H, Dealing A, Christiansen C, Rodbro P, Naestoft J 1982 Corticosteroid-induced osteopenia and vitamin D metabolism. Effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol (Oxf) 16:409-415
43. Kimberg DV, Baerg RD, Gershon E, Graudusius RT 1971 Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest 50:1309-1321
44. Lund B, Storm TL, Melsen F, Mosekilde L, Andersen RB, Egmose C, Sorensen OH 1985 Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment. Clin Rheumatol 4:143-149
45. Suzuki Y, Ichikawa Y, Saito E, Homma M 1983 Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32:151-156
46. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH 1979 Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 64:655-665
47. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV 1984 Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 36:245-252
48. Lukert BP, Adams JS 1976 Calcium and phosphorus homeostasis in man. Effect of corticosteroids. Arch Intern Med 136:1249-1253
49. Guo CY, Weiler H, Atkinson SA 2001 Elevated intact parathyroid hormone is associated with reduced biochemical markers of bone formation and resorption measured in blood in infant piglets receiving oral dexamethasone for 15 days. Biol Neonate 80:295-299
50. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R 1994 High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 9:1097-1105
51. Gram J, Junker P, Nielsen HK, Bollerslev J 1998 Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 23:297-302
52. Hahn TJ, Halstead LR, Baran DT 1981 Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111-115
53. Slovik DM, Neer RM, Ohman JL, Lowell FC, Clark MB, Segre GV, Potts Jr JT 1980 Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin Endocrinol (Oxf) 12:243-248
54. Fucik RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA 1975 Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 40:152-155
55. Peraldi MN, Rondeau E, Jousset V, el M'Selmi A, Lacave R, Delarue F, Garel JM, Sraer JD 1990 Dexamethasone increases preproparathyroid hormone messenger RNA in human hyperplastic parathyroid cells in vitro. Eur J Clin Invest 20:392-397
56. Yamamoto I, Potts Jr JT, Segre GV 1988 Glucocorticoids increase parathyroid hormone receptors in rat osteoblastic osteosarcoma cells (ROS 17/2). J Bone Miner Res 3:707-712
57. Rodan SB, Fischer MK, Egan JJ, Epstein PM, Rodan GA 1984 The effect of dexamethasone on parathyroid hormone stimulation of adenylate cyclase in ROS 17/2.8 cells. Endocrinology 115:951-958
58. Urena P, Iida-Klein A, Kong XF, Juppner H, Kronenberg HM, Abou-Samra AB, Segre GV 1994 Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells. Endocrinology 134:451-456
59. Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Chihara K 1997 Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res 12:734-741
60. Conaway HH, Grigorie D, Lerner UH Differential effects of glucocorticoids on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones. J Endocrinol 155:513-521
61. Seeman E, Kumar R, Hunder GG, Scott M, Heath 3rd H, Riggs BL 1980 Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess. J Clin Invest 66:664-669
62. Leboff MS, Wade JP, Mackowiak S, el-Hajj Fuleihan G, Zangari M, Liang MH 1991 Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J Rheumatol 18:339-344
63. Paz-Pacheco E, Fuleihan GE, LeBoff MS 1995 Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res 10:1713-1718
64. Hattersley AT, Meeran K, Burrin J, Hill P, Shiner R, Ibbertson HK 1994 The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int 54:198-202
65. Nielsen HK, Thomsen K, Eriksen EF, Charles P, Storm T, Mosekilde L 1988 The effects of high-dose glucocorticoid administration on serum bone γ carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 4:105-113
66. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E 1998 Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83:801-806
67. Manelli F, Bossoni S, Bugari G, Carpinteri R, Godi D, Agabiti Rosei E, Veldhuis JD, Giustina A, Chronic glucocorticoid treatment alters the spontaneous pulsatile parathyroid hormone (PTH) secretory pattern in humans. Proc of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 125 (Abstract OR 42-6)
68. Laan RF, Buijs WC, van Erning LJ, Lemmens JA, Corstens FH, Ruijs SH, van de Putte LB, van Riel PL 1993 Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 52:5-9
69. Reid IR, Heap SW 1990 Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 150:2545-2548
70. Reid IR, Evans MC, Stapleton J 1992 Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res 7:1221-1225
71. Lo Cascio V, Bonucci E, Imbimbo B, Ballanti P, Tartarotti D, Galvanini G, Fuccella L, Adami S 1984 Bone loss after glucocorticoid therapy. Calcif Tissue Int 36:435-438
72. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW 1991 Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 6 (Suppl 2):S85-S89, S121-S124
73. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezikian JP 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291
74. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709
75. Khosla S, Melton 3rd LJ, Wermers RA, Crowson CS, O'Fallon W, Riggs B 1999 Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700-1707
76. Kenny AM, MacGillivray DC, Pilbeam CC, Crombie HD, Raisz LG 1995 Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 118:109-114
77. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M. 1996 Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11:676-685
78. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian J.P., Dempster D.W. 1990 The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 70:930-938
79. Parisien M, Mellish RW, Silverberg SJ, Shane E, Lindsay R, Bilezikian J.P., Dempster D.W. 1992 Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 7:913-919
80. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero N, Meunier PJ 2001 Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97-103
81. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP 1999 On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:1562-1566
82. MacDonald BR, Gallagher JA, Russell RG 1986 Parathyroid hormone stimulates the proliferation of cells derived from human bone. Endocrinology 118:2445-2449
83. Manolagas SC, Weinstein RS 1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061-1066
84. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282
85. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446
86. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteodast differentiation and activation. Cell 93:165-176
87. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
88. Hofbauer LC, Heufelder AE 2000 Clinical review 114: hot topic. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355-2363
89. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
90. Sasaki N, Kusano E, Ando, Yano K, Tsuda E, Asano Y 2001 Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 16:479-482
91. Morony S, Lu J, Capparelli C, Dunstan CR, Lacey DL, Kostenuik PJ, Osteoprotegerin (OPG) prevents bone loss in a rat model of glucocorticoid-induced osteopenia. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, AZ, 2001, p S148 (Abstract 1046)
92. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE 2001 Catabolic effects of continuous human pth (1-38) in vivo is associated with sustained stimulation of rank1 and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054
93. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ 2000 In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871
94. Locklin RM, Khosla S, Riggs BL 2001 Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells. Bone 28:S80
95. Lam J, Ross FP, Teitelbaum SL, RANK ligand stimulates anabolic bone formation. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, AZ, 2001, p S150 (Abstract 1053)
96. Bauer W, Aub JC, Albright F 1929 Studies of calcium and phosphorous metabolism. J Exp Med 49:145-161
97. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, Bilezikian JP 1995 Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 80:723-728
98. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623
99. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134
100. Roe EB, Sanchez SD, Puerto AG, Pierini E, Bacchetti P, Cann CE, Arnaud CD, Treatment of postmenopausal osteoporosis with human PTH 1-34 and estrogen. Proc of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, 1999, p 59 (Abstract S63-1)
101. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925-931
102. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
103. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15:944-951